FDA Says No to Skin Cure, Chaos Ensues—Oops!

In a totally thrilling plot twist, the FDA's top cancer drug regulator decisively rejected Replimune Group's skin cancer therapy. STAT reveals the regulator 'played a key role' in blocking this treatment, proving once again that the path to progress is paved with perfectly timed bureaucratic pauses. Imagine the excitement as we watch how 'everything happens for a reason!' At least now, everyone has a chance to sharpen their patience skills and policymakers get to throw a bigger, better brainstorming party. What a blessing for the community spirit!

Share the Story

(1 of 3)
Swipe to navigate

Source: Statnews | Published: 8/4/2025 | Author: Adam Feuerstein